Serum Levels of Total-RANKL in Multiple Myeloma-Reference-Cited by-同舟云学术

Serum Levels of Total-RANKL in Multiple Myeloma

Published:2009-12 Issue:6 Volume:9 Page:430-435
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Jakob Christian,Goerke Andrea,Terpos Evangelos,Sterz Jan,Heider Ulrike,Kühnhardt Dagmar,Ziefle Susanne,Kleeberg Lorenz,Mieth Maren,von Metzler Ivana,Müller Christian,Sezer Orhan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference47 articles.

1. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma;Bataille;J Clin Invest,1991

2. Consequences of interactions between the bone marrow stroma and myeloma;Epstein;Hematol J,2003

3. Myeloma cells (5TMM) and their interactions with the marrow microenvironment;Menu;Blood Cells Mol Dis,2004

4. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma;Gunn;Stem Cells,2006

5. RANK ligand and osteoprotegerin in myeloma bone disease;Sezer;Blood,2003

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating sRANKL, Periostin, and Osteopontin as Biomarkers for the Assessment of Activated Osteoclastogenesis in Myeloma Related Bone Disease;Cancers;2023-11-24

2. The use of bone-modifying agents in multiple myeloma;Blood Reviews;2023-01

3. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval;Journal of Bone Oncology;2022-04

4. Pathogenesis and treatment of multiple myeloma bone disease;Japanese Dental Science Review;2021-11

5. Immunological Prognostic Factors in Multiple Myeloma;International Journal of Molecular Sciences;2021-03-30